This page provides educational resources, events, news and products related to psychedelics. Content will cover aspects from the impact of psychedelics on the brain to their therapeutic potential.
Psychedelics – Highlights
Ketamine, MDMA, DMT and Psilocybin: A Closer Look at Four Psychedelics
Treatments using psychedelics are making waves in psychiatric medicine. In this article we explore the background, mechanisms of action and therapeutic applications of four leading psychedelic drugs.
An Introduction to Five Psychedelics: Psilocybin, DMT, LSD, MDMA and Ketamine
Interest in the therapeutic potential of psychedelics, having lain relatively dormant in the face of stigma and heavy regulations for decades, has reignited in the last ten years. Landmark studies showing these compounds’ effectiveness in treating some mood disorders have kickstarted a wave of clinical research, with well over 100 separate trials now investigating psychedelics’ health applications.
The Neuroscience of Psychedelic Drugs: Your Brain on Psilocybin With Frederick Streeter Barrett
Fred Barrett is an Assistant Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University in Baltimore. In this interview, we discuss his work with the active component of magic mushrooms, psilocybin. Fred explains how this compound affects the brain, its potential to combat visceral pain, and its links to so-called mystical experiences.
Study Reveals DMT’s Effects on the Human Brain in Unprecedented Detail
A new study has unveiled how psychedelics achieve their perception-altering effects in the human brain. The research used a powerful combination of brain analysis techniques to provide the clearest picture yet of how the short-acting, but powerful psychedelic DMT (dimethyltryptamine) affects brain activity.
The Pulse: Psychedelic News From Technology Networks Issue 2
Hello and welcome to the Pulse, the monthly psychedelics industry roundup from Technology Networks and Analytical Cannabis. Here, we’ll highlight some of the most significant psychedelic industry news from the past month, including important announcements, pre-clinical work and the latest from groundbreaking psychedelic clinical trials.
Hormone Shot Sobers Up Drunk Mice
Researchers at the University of Texas Southwestern (UT Southwestern) Medical Center found they could protect mice against loss of balance and disorientation induced by ethanol through administering a hormone. The research is published in Cell.
The Pulse: Psychedelic News From Technology Networks
In the Pulse, the monthly psychedelics industry roundup from Technology Networks and Analytical Cannabis, we highlight some of the most significant psychedelic industry news from the past month. This includes important announcements, pre-clinical work and the latest from groundbreaking psychedelic clinical trials.
Ketamine Trialed To Treat Cocaine Use Disorders
A study has found that ketamine was associated with significant improvement in remission among people with cocaine-use disorders.
MAPS and Wesana Health Resume Final Negotiations
Analysis indicates viability of research pathway for MDMA-assisted therapy to treat symptoms associated with traumatic brain injury.
Wesana Health Commits Funding of $1.5 Million To Support MAPS’ Research Pipeline
Wesana Health announced its commitment to fund an initial US $1.5 million to assess the viability of Multidisciplinary Association for Psychedelic Studies (MAPS) MDMA-assisted therapy to treat traumatic brain injury (TBI).
Awakn Life Sciences Initiates the First Ketamine Treatment Study for Gambling Addiction
Awakn Life Sciences Corp. has announced that it has received ethical committee approval and has initiated recruitment for the first-ever study investigating ketamine in gambling addiction.